试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-27
Dose-finding PKPD Trial for RE02 in Healthy Subjects
编号:NCT05979727登记状态:提前终止企业 / 申办者:Reconnect Labs
药物 / 成分:RE02、Manitol
登记的停止原因(原文):The trial was closed due to futility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-26
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
编号:NCT04526509登记状态:提前终止企业 / 申办者:Adaptimmune
药物 / 成分:GSK3901961、GSK3845097、GSK4427296、Cyclophosphamide
登记的停止原因(原文):The study was terminated due to a change in GSK's R\&D priorities.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-26
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
编号:NCT04607668登记状态:提前终止企业 / 申办者:G1 Therapeutics, Inc.
药物 / 成分:Trilaciclib、Placebo
登记的停止原因(原文):The Sponsor made the decision to terminate the study and complete the final analysis for available data.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-26
Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts
编号:NCT04657679登记状态:提前终止企业 / 申办者:Georgetown University
药物 / 成分:Ribociclib
登记的停止原因(原文):Sufficient accrual into the African American/Black patient cohort and insufficient accrual into the NHW patient cohort.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-26
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
编号:NCT04951115登记状态:提前终止企业 / 申办者:Weill Medical College of Cornell University
药物 / 成分:Carboplatin、Cisplatin、Etoposide、Durvalumab
登记的停止原因(原文):The study was terminated early due to low accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-26
To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
编号:NCT05607446登记状态:提前终止企业 / 申办者:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
药物 / 成分:TQC3564 tablets、Placebo tablets、TQC3564 tablets, montelukast sodium tablets、Placebo tablets, montelukast sodium tablets
登记的停止原因(原文):This study was closed per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-25
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
编号:NCT02702492登记状态:提前终止企业 / 申办者:Karyopharm Therapeutics Inc
药物 / 成分:KPT-9274、Niacin ER、Nivolumab
登记的停止原因(原文):sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-25
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
编号:NCT02864953登记状态:提前终止企业 / 申办者:Remedy Pharmaceuticals, Inc.
药物 / 成分:BIIB093、Placebo
登记的停止原因(原文):Early completed to operational challenges and other strategic considerations, not for efficacy or safety reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-25
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
编号:NCT03009058登记状态:提前终止企业 / 申办者:Immodulon Therapeutics Ltd
药物 / 成分:IMM-101、Gemcitabine、Nab-paclitaxel、Capecitabine
登记的停止原因(原文):Commercial reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-25
Metabolic Effects of Natriuretic Peptide Hormones
编号:NCT03397966登记状态:提前终止企业 / 申办者:VA Office of Research and Development
药物 / 成分:recombinant human BNP(1-32)、placebo (control, normal saline)
登记的停止原因(原文):Study drug no longer available
查看官方原始记录 ↗